Liminal BioSciences Inc. PFSCF

RE:RE:RE:NR: Trading on nasdaq next monday!

[aldo451]

Speaking of clueless meatheads, just yesterday from the guy who has it all figured out...has no shares, (so he claims) not interested in buying, but bashes 20 times a day...go figure!
 
You are the biggest meathead on this board.

PLITheOne (144)

User Actions  

November 14, 2019 - 01:57 PM 13 Reads
Post# 30351989

RE:i also say these bashers are loading up

THERE WILL BE NO NASDAQ THIS YEAR!!!
Just more loses...

Read more at https://stockhouse.com/companies/bullboard/t.pli/liminal-biosciences-inc?postid=30351989#CrQ4X5vLdI6s321C.99

PLITheOne wrote: So happy for you clueless meathead. 
Have a lovely weekend. 

Newcamo wrote:

SPammers told you would never happen. Trust no one on this board! Do your dd, listen to the latest webcast, its all there! Congrats Thomvest!

 

 

conradj wrote:

 

Trading nasdaq and TSX as well!

Liminal BioSciences to Commence Trading Common Shares on NASDAQ

Canada NewsWire

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, Nov. 15, 2019

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, Nov. 15, 2019 /CNW Telbec/ - Liminal BioSciences Inc. (TSX: LMNL) (OTCQX: PFSCF) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, announced today that it has filed a Form 40-F Registration Statement with the U.S. Securities and Exchange Commission ("SEC"),which has become effective, and its common shares have been approved for trading on the Nasdaq Global Market ( "NASDAQ"). Trading is expected to commence on NASDAQ on Monday, November 18, 2019, under the ticker symbol 'LMNL'. The Company's common shares will continue to trade on the Toronto Stock Exchange under the symbol "LMNL".

"Having our common shares traded on NASDAQ represents an important step for Liminal, as we continue to focus on the successful development and commercialization of our proprietary clinical-stage products, including Ryplazim™ and PBI-4050", stated Kenneth Galbraith, Chief Executive Officer of the Company.